نتایج جستجو برای: rituximab

تعداد نتایج: 11050  

Journal: :ژورنال پزشکی بین المللی الکترونیک 0
sara saniee armaghan ghare aghaji zare

psoriasis and pemphigus vulgaris are two inflammatory and autoimmune diseases. their concomitant occurrence in one patient is very rare. we describe a 57-year-old patient with a history of severe plaque type psoriasis for 2 years. after a few months, he presented with disseminated bullae and mucosal erosions which were documented as pemphigus vulgaris. both of the diseases were successfully con...

NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...

Journal: :مجله دانشگاه علوم پزشکی شهید صدوقی یزد 0
محمد باقر اولیاء mb owlia گلبرگ مهرپور g mehrpoor . [email protected]

summary: adult-onset still’s disease (aosd) is a rare systemic inflammatory disorder of unknown etiology. it is characterized by high grade fever, skin rash, arthritis, leukocytosis, increased esr, crp and liver enzyme levels and high levels of ferritin. the treatment of aosd includes nsaids, steroids, and disease-modifying antirheumatic drugs (dmards). recently biologic agents have been used f...

اولیاء, محمد باقر, مهرپور, گلبرگ,

Summary: Adult-onset Still’s disease (AOSD) is a rare systemic inflammatory disorder of unknown etiology. It is characterized by high grade fever, skin rash, arthritis, leukocytosis, increased ESR, CRP and liver enzyme levels and high levels of ferritin. The treatment of AOSD includes NSAIDs, steroids, and disease-modifying antirheumatic drugs (DMARDs). Recently biologic agents have been used ...

Journal: :iranian journal of radiation research 0
a. r. jalilian department of cyclotron & nuclear medicine, nuclear research center for agriculture and medicine, karaj, iran l. mirsadegh department of biochemistry, payam-e-noor university, tehran, iran r. haji-hosseini department of biochemistry, payam-e-noor university, tehran, iran s. rajabifar department of cyclotron & nuclear medicine, nuclear research center for agriculture and medicine, karaj, iran f. bolurinovin department of cyclotron & nuclear medicine, nuclear research center for agriculture and medicine, karaj, iran

background: in order to obtain an anti-cd20 conjugate to be used in future therapeutic studies with therapeutic radioisotopes, 67ga-labeled antibody was prepared as a model of metal chelated immunoconjugate for preliminary dosimetric and biodistribution studies. materials and methods: rituximab was labeled with [67ga]-gallium chloride after residulation with freshly prepared cyclic dtpadianhydr...

NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...

2018
Anne-Sophie Michallet Melih Aktan Wolfgang Hiddemann Osman Ilhan Peter Johansson Kamel Laribi Balkis Meddeb Carol Moreno João Raposo Anna Schuh Ali Ünal Tom Widenius Alf Bernhardt Kerstin Kellershohn Dimitri Messeri Stuart Osborne Véronique Leblond

MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia. Patients received rituximab plus bendamustine or rituximab plus chlorambucil every four weeks for six cycles. Rituximab plus chlorambucil-treated patients without a complete response after Cycle 6 received chlorambucil mon...

Radioimmunotherapy (RIT) of Non-Hodgkin’s lymphoma (NHL) is said to be more advantageous compared to unlabelled therapeutic antibodies. To this date, radiolabelled murine anti-CD20 mAbs, Zevalin® and Bexxar® have been approved for imaging and therapy. A preparation containing rituximab, chimeric mAb radioimmunoconjugate suitable for Lu-177 labeling, could provide better imaging and therapeutic ...

Journal: :British journal of haematology 2011
Steven P Treon Christina Hanzis Robert J Manning Leukothea Ioakimidis Christopher J Patterson Zachary R Hunter Patricia Sheehy Barry Turnbull

This study examined the outcome of 248 Waldenstrom macroglobulinaemia (WM) rituximab-naïve patients who responded to a rituximab-containing regimen. Eighty-six patients (35%) subsequently received maintenance rituximab (M-Rituximab). No differences in baseline characteristics, and post-induction categorical responses between cohorts were observed. The median rituximab infusions during induction...

Journal: :iranian journal of pharmaceutical research 0
darinka gjorgieva ackova department of pharmacy, faculty of medical sciences, university "goce delcev"- stip, republic of macedonia katarina smilkov department of pharmacy, faculty of medical sciences, university goce delcev-stip, republic of macedonia emilija janevik-ivanovska department of pharmacy, faculty of medical sciences, university goce delcev-stip, republic of macedonia

radioimmunotherapy (rit) of non-hodgkin’s lymphoma (nhl) is said to be more advantageous compared to unlabelled therapeutic antibodies. to this date, radiolabelled murine anti-cd20 mabs, zevalin® and bexxar® have been approved for imaging and therapy. a preparation containing rituximab, chimeric mab radioimmunoconjugate suitable for lu-177 labeling, could provide better imaging and therapeutic ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید